Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tokuyama ( (JP:4043) ) has shared an update.
Tokuyama reported third-quarter fiscal 2025 consolidated results showing essentially flat net sales at ¥251.5 billion but a strong improvement in profitability, with operating profit up 26.9% to ¥26.7 billion and profit attributable to owners of parent rising 11.5% to ¥18.9 billion, alongside a jump in comprehensive income and an increase in total assets and shareholders’ equity. The company maintained an aggressive shareholder return stance by raising annual dividend guidance to ¥120 per share from ¥100 in the previous year and announced an upward revision to its full-year fiscal 2025 forecast, now expecting modest sales growth but around 30% gains in operating and ordinary profit and a 17.6% increase in full-year net profit, while expanding its consolidation scope to include seven new life-science-related subsidiaries, a move that signals strategic reinforcement of its medical and biotech portfolio and potentially strengthens its long-term earnings base and industry positioning.
The most recent analyst rating on (JP:4043) stock is a Buy with a Yen4989.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.
More about Tokuyama
Tokuyama Corporation is a Japan-based chemical manufacturer listed on the Tokyo Stock Exchange, operating across businesses such as basic chemicals, specialty materials and life sciences, with a growing focus on medical and biological fields as evidenced by recent consolidation of multiple biotech and diagnostics-related subsidiaries in Japan and China.
Average Trading Volume: 389,011
Technical Sentiment Signal: Buy
Current Market Cap: Yen324.4B
Learn more about 4043 stock on TipRanks’ Stock Analysis page.